Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203722 | 0.78 | ATM (0.52) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL3082371 | 0.78 | ATM (0.52) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL27396631 | 0.76 | ATM (0.50) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL27978837 | 0.76 | ATM (0.50) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL2184936 | 0.76 | ATM (0.50) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6050178 | 0.74 | L3MBTL1 (0.48) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL5315426 | 0.74 | ATM (0.48) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL2186918 | 0.74 | ATM (0.48) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL5312699 | 0.74 | ATM (0.48) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL14738408 | 0.73 | SMN1; SMN2 (0.47) | ATMALDH1A1SMN1; SMN2L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | ATM 2599/4885ALDH1A1 171/4885SMN1; SMN2 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.